ProPhase Labs, Inc. (PRPH)
USD 0.3
(-2.27%)
USD 0.3
(-2.27%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 16.23 Million USD | -77.02% |
| 2022 | 70.65 Million USD | 115.32% |
| 2021 | 32.81 Million USD | 612.42% |
| 2020 | 4.6 Million USD | 76.14% |
| 2019 | 2.61 Million USD | -45.3% |
| 2018 | 4.78 Million USD | 145.43% |
| 2017 | 1.94 Million USD | -80.65% |
| 2016 | 10.06 Million USD | -17.34% |
| 2015 | 12.17 Million USD | -14.11% |
| 2014 | 14.17 Million USD | -14.95% |
| 2013 | 16.67 Million USD | 16.97% |
| 2012 | 14.25 Million USD | 26.33% |
| 2011 | 11.28 Million USD | 27.77% |
| 2010 | 8.83 Million USD | -23.68% |
| 2009 | 11.56 Million USD | 1.37% |
| 2008 | 11.41 Million USD | -49.61% |
| 2007 | 22.64 Million USD | -1.01% |
| 2006 | 22.87 Million USD | -17.8% |
| 2005 | 27.83 Million USD | 36.61% |
| 2004 | 20.37 Million USD | 1.82% |
| 2003 | 20.01 Million USD | 63.87% |
| 2002 | 12.21 Million USD | -18.88% |
| 2001 | 15.05 Million USD | 11.68% |
| 2000 | 13.47 Million USD | -21.17% |
| 1999 | 17.1 Million USD | -33.46% |
| 1998 | 25.7 Million USD | -47.44% |
| 1997 | 48.9 Million USD | 6012.5% |
| 1996 | 800 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -476 Thousand USD | -9.93% |
| 2024 Q1 | -433 Thousand USD | 85.83% |
| 2023 Q1 | 10.52 Million USD | -6.76% |
| 2023 Q4 | -3.05 Million USD | -231.33% |
| 2023 FY | 16.23 Million USD | -77.02% |
| 2023 Q3 | 2.32 Million USD | -63.91% |
| 2023 Q2 | 6.44 Million USD | -38.71% |
| 2022 FY | 70.65 Million USD | 115.32% |
| 2022 Q4 | 11.28 Million USD | -5.76% |
| 2022 Q3 | 11.97 Million USD | -36.04% |
| 2022 Q2 | 18.72 Million USD | -34.72% |
| 2022 Q1 | 28.67 Million USD | 85.68% |
| 2021 Q4 | 15.44 Million USD | 288.33% |
| 2021 FY | 32.81 Million USD | 612.42% |
| 2021 Q2 | 4.46 Million USD | -49.97% |
| 2021 Q1 | 8.92 Million USD | 377.38% |
| 2021 Q3 | 3.97 Million USD | -10.95% |
| 2020 Q4 | 1.87 Million USD | 79.46% |
| 2020 Q1 | 415 Thousand USD | -58.5% |
| 2020 Q3 | 1.04 Million USD | -18.53% |
| 2020 Q2 | 1.27 Million USD | 208.19% |
| 2020 FY | 4.6 Million USD | 76.14% |
| 2019 Q4 | 1 Million USD | 19.9% |
| 2019 FY | 2.61 Million USD | -45.3% |
| 2019 Q3 | 834 Thousand USD | 219.54% |
| 2019 Q2 | 261 Thousand USD | -49.81% |
| 2019 Q1 | 520 Thousand USD | -61.22% |
| 2018 Q2 | 1.25 Million USD | -11.72% |
| 2018 FY | 4.78 Million USD | 145.43% |
| 2018 Q1 | 1.42 Million USD | 10.29% |
| 2018 Q3 | 756 Thousand USD | -39.9% |
| 2018 Q4 | 1.34 Million USD | 77.38% |
| 2017 Q3 | 432 Thousand USD | 208.57% |
| 2017 Q2 | 140 Thousand USD | 64.71% |
| 2017 Q4 | 1.29 Million USD | 199.07% |
| 2017 Q1 | 85 Thousand USD | -97.79% |
| 2017 FY | 1.94 Million USD | -80.65% |
| 2016 Q3 | 2.15 Million USD | 91.39% |
| 2016 Q2 | 1.12 Million USD | -61.69% |
| 2016 Q4 | 3.84 Million USD | 78.47% |
| 2016 Q1 | 2.93 Million USD | -38.62% |
| 2016 FY | 10.06 Million USD | -17.34% |
| 2015 Q4 | 4.78 Million USD | 76.09% |
| 2015 Q3 | 2.71 Million USD | 170.01% |
| 2015 Q1 | 3.66 Million USD | -37.9% |
| 2015 FY | 12.17 Million USD | -14.11% |
| 2015 Q2 | 1 Million USD | -72.5% |
| 2014 FY | 14.17 Million USD | -14.95% |
| 2014 Q1 | 3.98 Million USD | -39.58% |
| 2014 Q2 | 792 Thousand USD | -80.1% |
| 2014 Q3 | 3.51 Million USD | 343.18% |
| 2014 Q4 | 5.89 Million USD | 68.01% |
| 2013 Q3 | 3.81 Million USD | 311.31% |
| 2013 Q2 | 928 Thousand USD | -82.62% |
| 2013 Q1 | 5.33 Million USD | -6.14% |
| 2013 FY | 16.67 Million USD | 16.97% |
| 2013 Q4 | 6.58 Million USD | 72.57% |
| 2012 Q3 | 3.39 Million USD | 312.0% |
| 2012 Q1 | 4.34 Million USD | -9.55% |
| 2012 Q4 | 5.68 Million USD | 67.34% |
| 2012 Q2 | 825 Thousand USD | -80.99% |
| 2012 FY | 14.25 Million USD | 26.33% |
| 2011 Q3 | 3.59 Million USD | 301.34% |
| 2011 Q1 | 1.99 Million USD | -44.29% |
| 2011 Q2 | 896 Thousand USD | -55.07% |
| 2011 FY | 11.28 Million USD | 27.77% |
| 2011 Q4 | 4.79 Million USD | 33.43% |
| 2010 Q1 | 1.17 Million USD | -77.97% |
| 2010 Q3 | 3.61 Million USD | 666.45% |
| 2010 FY | 8.83 Million USD | -23.68% |
| 2010 Q4 | 3.57 Million USD | -0.86% |
| 2010 Q2 | 471 Thousand USD | -59.74% |
| 2009 Q2 | 291.07 Thousand USD | -87.63% |
| 2009 FY | 11.56 Million USD | 1.37% |
| 2009 Q1 | 2.35 Million USD | -17.85% |
| 2009 Q4 | 5.31 Million USD | 46.92% |
| 2009 Q3 | 3.61 Million USD | 1141.96% |
| 2008 Q4 | 2.86 Million USD | -29.86% |
| 2008 Q3 | 4.08 Million USD | 354.64% |
| 2008 Q1 | 3.56 Million USD | -58.48% |
| 2008 Q2 | 897.9 Thousand USD | -74.85% |
| 2008 FY | 11.41 Million USD | -49.61% |
| 2007 Q3 | 6.93 Million USD | 230.04% |
| 2007 FY | 22.64 Million USD | -1.01% |
| 2007 Q1 | 5.01 Million USD | -44.31% |
| 2007 Q2 | 2.1 Million USD | -58.03% |
| 2007 Q4 | 8.59 Million USD | 23.89% |
| 2006 Q3 | 6.25 Million USD | 171.05% |
| 2006 FY | 22.87 Million USD | -17.8% |
| 2006 Q4 | 8.99 Million USD | 43.72% |
| 2006 Q2 | 2.3 Million USD | -56.53% |
| 2006 Q1 | 5.31 Million USD | -50.82% |
| 2005 Q1 | 5.7 Million USD | -38.53% |
| 2005 Q2 | 3.03 Million USD | -46.81% |
| 2005 FY | 27.83 Million USD | 36.61% |
| 2005 Q3 | 8.29 Million USD | 173.42% |
| 2005 Q4 | 10.8 Million USD | 30.25% |
| 2004 Q3 | 3.8 Million USD | 36.85% |
| 2004 Q1 | 4.52 Million USD | -50.13% |
| 2004 Q2 | 2.77 Million USD | -38.57% |
| 2004 Q4 | 9.27 Million USD | 144.14% |
| 2004 FY | 20.37 Million USD | 1.82% |
| 2003 Q4 | 9.06 Million USD | 101.96% |
| 2003 Q2 | 2.76 Million USD | -25.14% |
| 2003 Q3 | 4.48 Million USD | 62.27% |
| 2003 FY | 20.01 Million USD | 63.87% |
| 2003 Q1 | 3.69 Million USD | -1.48% |
| 2002 Q2 | 2.11 Million USD | -27.57% |
| 2002 Q4 | 3.74 Million USD | 9.12% |
| 2002 Q3 | 3.43 Million USD | 62.79% |
| 2002 Q1 | 2.91 Million USD | -44.77% |
| 2002 FY | 12.21 Million USD | -18.88% |
| 2001 Q3 | 3.87 Million USD | 141.14% |
| 2001 FY | 15.05 Million USD | 11.68% |
| 2001 Q1 | 3.01 Million USD | -46.83% |
| 2001 Q2 | 1.6 Million USD | -46.75% |
| 2001 Q4 | 5.27 Million USD | 36.15% |
| 2000 Q4 | 5.67 Million USD | 120.8% |
| 2000 FY | 13.47 Million USD | -21.17% |
| 2000 Q3 | 2.57 Million USD | 188.63% |
| 2000 Q2 | 890.88 Thousand USD | -79.47% |
| 2000 Q1 | 4.33 Million USD | -51.24% |
| 1999 FY | 17.1 Million USD | -33.46% |
| 1999 Q1 | 4 Million USD | -67.21% |
| 1999 Q2 | 1.4 Million USD | -65.0% |
| 1999 Q3 | 2.7 Million USD | 92.86% |
| 1999 Q4 | 8.9 Million USD | 229.63% |
| 1998 Q4 | 12.2 Million USD | 62.67% |
| 1998 Q1 | 5.1 Million USD | -74.75% |
| 1998 Q3 | 7.5 Million USD | 733.33% |
| 1998 FY | 25.7 Million USD | -47.44% |
| 1998 Q2 | 900 Thousand USD | -82.35% |
| 1997 Q1 | 15.3 Million USD | 462.5% |
| 1997 Q4 | 20.2 Million USD | 94.23% |
| 1997 Q2 | 2.9 Million USD | -81.05% |
| 1997 FY | 48.9 Million USD | 6012.5% |
| 1997 Q3 | 10.4 Million USD | 258.62% |
| 1996 FY | 800 Thousand USD | 0.0% |
| 1996 Q4 | 2.72 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 95.021% |
| Embecta Corp. | 749.9 Million USD | 97.835% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 94.681% |
| Dynavax Technologies Corporation | 182.11 Million USD | 91.083% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 77.775% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 96.688% |
| PainReform Ltd. | -15 Thousand USD | 108360.0% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | 45.419% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -94.732% |
| SCYNEXIS, Inc. | 124.51 Million USD | 86.958% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -2831.381% |
| Cosmos Health Inc. | 4.34 Million USD | -273.347% |
| Journey Medical Corporation | 52.52 Million USD | 69.081% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -94.732% |
| Safety Shot Inc | -74.45 Thousand USD | 21909.904% |
| Alpha Teknova, Inc. | 10.29 Million USD | -57.721% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 96.229% |
| Bright Green Corporation | -237.01 Thousand USD | 6951.436% |
| Procaps Group, S.A. | 239.56 Million USD | 93.222% |
| Theratechnologies Inc. | 62.12 Million USD | 73.862% |
| Harrow Health, Inc. | 90.55 Million USD | 82.067% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -242.234% |
| Biofrontera Inc. | 16.62 Million USD | 2.334% |
| DURECT Corporation | 6.83 Million USD | -137.725% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 96.899% |
| Cronos Group Inc. | 6.99 Million USD | -132.288% |
| OptiNose, Inc. | 62.35 Million USD | 73.957% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 96.319% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 5459.406% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -431.699% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 94.758% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -201.028% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 51.505% |
| Radius Health, Inc. | 307.71 Million USD | 94.723% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -61.135% |
| Phibro Animal Health Corporation | 312.48 Million USD | 94.803% |
| Procaps Group S.A. | 239.56 Million USD | 93.222% |
| Alvotech | -69.42 Million USD | 123.392% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -1147.235% |
| Viatris Inc. | 6.43 Billion USD | 99.748% |
| Rockwell Medical, Inc. | 8.7 Million USD | -86.569% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 70.251% |
| SIGA Technologies, Inc. | 122.09 Million USD | 86.699% |
| Tilray Brands, Inc. | 223.35 Million USD | 92.729% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 61.197% |
| Shineco, Inc. | 882.16 Thousand USD | -1740.806% |
| PetIQ, Inc. | 252.74 Million USD | 93.575% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 2278.013% |
| Incannex Healthcare Limited | 12 Thousand USD | -135225.0% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.121% |
| Alimera Sciences, Inc. | 61.17 Million USD | 73.453% |
| Silver Spike Investment Corp. | 8.1 Million USD | -100.417% |
| Assertio Holdings, Inc. | 125.04 Million USD | 87.014% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 238523.139% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -287.458% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -147.697% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 773.768% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | 40.115% |
| Hempacco Co., Inc. | -1.21 Million USD | 1435.628% |
| Talphera, Inc. | -4.89 Million USD | 431.747% |
| Alvotech | -69.42 Million USD | 123.392% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 92.674% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 97.711% |
| Currenc Group, Inc. | 17.35 Million USD | 6.437% |
| Kamada Ltd. | 52.59 Million USD | 69.123% |
| Indivior PLC | 907 Million USD | 98.21% |
| Evoke Pharma, Inc. | 4.97 Million USD | -226.166% |
| Flora Growth Corp. | 17.73 Million USD | 8.451% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 773.768% |
| Evolus, Inc. | 140.52 Million USD | 88.444% |
| HUTCHMED (China) Limited | 453.55 Million USD | 96.42% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 95.279% |
| Akanda Corp. | 111.44 Thousand USD | -14470.79% |